Pasar al contenido principal

ESTUDIO DE LA QUASIESPECIES DEL GEN X EN ARN CIRCULANTE DEL VIRUS DE LA HEPATITIS B (ARN-VHB): EN BUSQUEDA DE NUEVOS FACTORES PRONOSTICOS Y DIANAS PARA TERAPIA GENICA

PI18/01436

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up

  • Riveiro Barciela, Maria del Mar
  • Tabernero Caellas, David
  • Rodriguez-Algarra, Francisco
  • Palom Agusti, Adriana
  • Sopena Santisteve, Sara
  • Kuchta, Alison
  • Ferrer Costa, Roser
  • Quer Sivila, Josep
  • Pacín Ruíz, Beatriz
  • Vila Salvador, Marta
  • Casillas Gomez, Rosario
  • Garcia Garcia, Selene
  • Esteban Mur, Rafael
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Roade Tato, Maria luisa
  • Rando Segura, Ariadna
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Antiviral treatment; Biomonitoring, Tratamiento antiviral; Biomonitorización, Tractament antiviral; Biomonitorització, The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log10 higher than corresponding RNA levels and were stable over 5 years of observation. While only five of 52 treated patients had DNA levels below the lower limit of quantification (10 IU/mL) at the end of follow-up, 13 had HBV RNA levels persistently above this limit, including eight with undetectable DNA. In samples with undetectable core-related antigen we observed a median HBsAg titer 2.7-fold higher than in samples with undetectable RNA (adjusted P = 0.012). Detectable HBV RNA with undetectable HBV DNA was a negative predictor of HBsAg decrease to a level ≤100 IU/mL (P = 0.03). In naive patients the difference between HBV DNA and RNA was higher than previously reported. HBV RNA rapidly decreased during treatment. However, in some cases, it was detectable even after years of effective therapy, being a negative predictor of HBsAg decrease. The investigational RNA assay for use on the Cobas 6800/8800 instruments is a sensitive and standardized method that could be applied in general management of HBV infection. IMPORTANCE This study focused on the quantification of circulating HBV RNA by using a standardized and sensitive assay. Thanks to this system we observed a higher difference between circulating HBV DNA and RNA than previously reported. In treated patients, HBV RNA decreased together with DNA, although some patients presented detectable levels even after years of successful antiviral treatment, suggesting a persistent viral transcription. Of note, the detection of viral RNA when HBV DNA is undetectable was a negative predictor of HBsAg decrease to a level ≤100 IU/mL. This assay could be extremely helpful in HBV patients management to study viral transcription and to identify those treated patients that may achieve sustained viral suppression., This study was supported by grants from the Institute of Health Carlos III (grant PI17/02233 and PI18/01436) and by the European Regional Development Fund (ERDF). The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hepatitis B Virus Variants with Multiple Insertions and/or Deletions in the X Open Reading Frame 3′ End: Common Members of Viral Quasispecies in Chronic Hepatitis B Patients

  • Garcia Garcia, Selene
  • Caballero Garralda, Andrea
  • Tabernero Caellas, David
  • Rodriguez-Algarra, Francisco
  • Quer Sivila, Josep
  • Riveiro Barciela, Maria del Mar
  • Homs, Maria
  • Pacín Ruiz, Beatriz
  • Vila Salvador, Marta
  • Ferrer Costa, Roser
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Hepatitis B virus; Insertions; Next-generation sequencing, Virus de l'hepatitis B; Insercions; Seqüenciació de nova generació, Virus de la hepatitis B; Inserciones; Secuenciación de próxima generación, Deletions in the 3′ end region of the hepatitis B virus (HBV) X open reading frame (HBX) may affect the core promoter (Cp) and have been frequently associated with hepatocellular carcinoma (HCC). The aim of this study was to investigate the presence of variants with deletions and/or insertions (Indels) in this region in the quasispecies of 50 chronic hepatitis B (CHB) patients without HCC. We identified 103 different Indels in 47 (94%) patients, in a median of 3.4% of their reads (IQR, 1.3–8.4%), and 25% (IQR, 13.1–40.7%) of unique sequences identified in each quasispecies (haplotypes). Of those Indels, 101 (98.1%) caused 44 different altered stop codons, the most commonly observed were at positions 128, 129, 135, and 362 (putative position). Moreover, 39 (37.9%) Indels altered the TATA-like box (TA) sequences of Cp; the most commonly observed caused TA2 + TA3 fusion, creating a new putative canonical TATA box. Four (8%) patients developed negative clinical outcomes after a median follow-up of 9.4 (8.7–12) years. In conclusion, we observed variants with Indels in the HBX 3′ end in the vast majority of our CHB patients, some of them encoding alternative versions of HBx with potential functional roles, and/or alterations in the regulation of transcription., This research was funded by Instituto de Salud Carlos III and co-financed by the European Regional Development Fund (ERDF), grant number PI18/01436; PI19/00301; and by the Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297. The APC was funded by the grant PI18/01436.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Conservation and variability of hepatitis B core at different chronic hepatitis stages

  • Yll, Marçal|||0000-0002-7030-3360
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Orriols, Gerard|||0000-0002-1138-5909
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Casillas, Rosario|||0000-0002-6758-6734
  • González, Carolina|||0000-0002-0169-5874
  • Sopena, Sara|||0000-0002-3309-5486
  • Godoy, Cristina|||0000-0001-5037-1916
  • Vila, Marta|||0000-0001-9303-5189
  • Tabernero, David|||0000-0002-1146-4084
  • Quer, Josep|||0000-0003-0014-084X
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Lopez Martinez, Rosa|||0000-0002-8450-6986
  • Esteban, Rafael|||0000-0001-5280-392X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
Since it is currently not possible to eradicate hepatitis B virus (HBV) infection with existing treatments, research continues to uncover new therapeutic strategies. HBV core protein, encoded by the HBV core gene (HBC), intervenes in both structural and functional processes, and is a key protein in the HBV life cycle. For this reason, both the protein and the gene could be valuable targets for new therapeutic and diagnostic strategies. Moreover, alterations in the protein sequence could serve as potential markers of disease progression. To detect, by next-generation sequencing, HBC hyper-conserved regions that could potentially be prognostic factors and targets for new therapies. Thirty-eight of 45 patients with chronic HBV initially selected were included and grouped according to liver disease stage [chronic hepatitis B infection without liver damage (CHB, n = 16), liver cirrhosis (LC, n = 5), and hepatocellular carcinoma (HCC, n = 17)]. HBV DNA was extracted from patients' plasma. A region between nucleotide (nt) 1863 and 2483, which includes HBC, was amplified and analyzed by next-generation sequencing (Illumina MiSeq platform). Sequences were genotyped by distance-based discriminant analysis. General and intergroup nt and amino acid (aa) conservation was determined by sliding window analysis. The presence of nt insertion and deletions and/or aa substitutions in the different groups was determined by aligning the sequences with genotype-specific consensus sequences. Three nt (nt 1900-1929, 2249-2284, 2364-2398) and 2 aa (aa 117-120, 159-167) hyper-conserved regions were shared by all the clinical groups. All groups showed a similar pattern of conservation, except for five nt regions (nt 1946-1992, 2060-2095, 2145-2175, 2230-2250, 2270-2293) and one aa region (aa 140-160), where CHB and LC, respectively, were less conserved (P < 0.05). Some group-specific conserved regions were also observed at both nt (2306-2334 in CHB and 1935-1976 and 2402-2435 in LC) and aa (between aa 98-103 in CHB and 28-30 and 51-54 in LC) levels. No differences in insertion and deletions frequencies were observed. An aa substitution (P79Q) was observed in the HCC group with a median (interquartile range) frequency of 15.82 (0-78.88) vs 0 (0-0) in the other groups (P < 0.05 vs CHB group). The differentially conserved HBC and HBV core protein regions and the P79Q substitution could be involved in disease progression. The hyper-conserved regions detected could be targets for future therapeutic and diagnostic strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

  • García López, Mireia|||0000-0002-9643-7172
  • Lens, Sabela|||0000-0003-4900-411X
  • Pallett, Laura J.
  • Testoni, Barbara
  • Rodríguez-Tajes, Sergio|||0000-0002-3189-7557
  • Mariño, Zoe|||0000-0001-6321-9534
  • Bartres, Concepció
  • García-Pras, Ester
  • Leonel, Thais
  • Perpiñán, Elena
  • Lozano, Juan José
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Koutsoudakis, George
  • Zoulim, Fabien
  • Maini, Mala K.
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Factors associated with a successful outcome upon nucleos(t)ide analogue (NA) treatment withdrawal in HBeAg-negative chronic hepatitis B (CHB) patients have yet to be clarified. The objective of this study was to analyse the HBV-specific T cell response, in parallel with peripheral and intrahepatic viral parameters, in patients undergoing NA discontinuation. Twenty-seven patients without cirrhosis with HBeAg-negative CHB with complete viral suppression (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients

  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • González, Carolina|||0000-0002-0169-5874
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Casillas, Rosario|||0000-0002-6758-6734
  • Carioti, Luca
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Godoy, Cristina|||0000-0001-5037-1916
  • Sopena, Sara|||0000-0002-3309-5486
  • Yll, Marçal|||0000-0002-7030-3360
  • Quer, Josep|||0000-0003-0014-084X
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Lopez Martinez, Rosa|||0000-0002-8450-6986
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • García-García, Selene|||0000-0001-7697-2058
  • Esteban, Rafael|||0000-0001-5280-392X
  • Tabernero, David|||0000-0002-1146-4084
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
Patients with HBeAg-negative chronic infection (CI) have not been extensively studied because of low viremia. The HBx protein, encoded by HBX, has a key role in viral replication. Here, we analyzed the viral quasispecies at the 5' end of HBX in CI patients and compared it with that of patients in other clinical stages. Fifty-eight HBeAg-negative patients were included: 16 CI, 19 chronic hepatitis B, 16 hepatocellular carcinoma and 6 liver cirrhosis. Quasispecies complexity and conservation were determined in the region between nucleotides 1255 and 1611. Amino acid changes detected were tested in vitro. CI patients showed higher complexity in terms of mutation frequency and nucleotide diversity and higher quasispecies conservation (p < 0.05). A genotype D-specific pattern of mutations (A12S/P33S/P46S/T36D-G) was identified in CI (median frequency, 81.7%), which determined a reduction in HBV DNA release of up to 1.5 log in vitro. CI patients showed a more complex and conserved viral quasispecies than the other groups. The genotype-specific pattern of mutations could partially explain the low viremia observed in these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hepatitis B Virus Variants with Multiple Insertions and/or Deletions in the X Open Reading Frame 3' End, Common Members of Viral Quasispecies in Chronic Hepatitis B Patients

  • García-García, Selene|||0000-0001-7697-2058
  • Caballero, Andrea|||0000-0003-2891-6347
  • Tabernero, David|||0000-0002-1146-4084
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rodriguez-Algarra, Francisco|||0000-0002-4134-2141
  • Quer, Josep|||0000-0003-0014-084X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Homs, Maria|||0000-0002-8370-8375
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Vila, Marta|||0000-0001-9303-5189
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
Deletions in the 3' end region of the hepatitis B virus (HBV) X open reading frame (HBX) may affect the core promoter (Cp) and have been frequently associated with hepatocellular carcinoma (HCC). The aim of this study was to investigate the presence of variants with deletions and/or insertions (Indels) in this region in the quasispecies of 50 chronic hepatitis B (CHB) patients without HCC. We identified 103 different Indels in 47 (94%) patients, in a median of 3.4% of their reads (IQR, 1.3-8.4%), and 25% (IQR, 13.1-40.7%) of unique sequences identified in each quasispecies (haplotypes). Of those Indels, 101 (98.1%) caused 44 different altered stop codons, the most commonly observed were at positions 128, 129, 135, and 362 (putative position). Moreover, 39 (37.9%) Indels altered the TATA-like box (TA) sequences of Cp; the most commonly observed caused TA2 + TA3 fusion, creating a new putative canonical TATA box. Four (8%) patients developed negative clinical outcomes after a median follow-up of 9.4 (8.7-12) years. In conclusion, we observed variants with Indels in the HBX 3' end in the vast majority of our CHB patients, some of them encoding alternative versions of HBx with potential functional roles, and/or alterations in the regulation of transcription.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA, Different quasispecies?

  • García-García, Selene|||0000-0001-7697-2058
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Vila, Marta|||0000-0001-9303-5189
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Quer, Josep|||0000-0003-0014-084X
  • Casillas, Rosario|||0000-0002-6758-6734
  • Castillo-Ribelles, Laura|||0000-0001-9380-7839
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Trejo-Zahínos, Jesús
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Casis-Saez, Ernesto
  • Esteban, Rafael|||0000-0001-5280-392X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
Different forms of pregenomic and other hepatitis B virus (HBV) RNA have been detected in patients' sera. These circulating HBV-RNAs may be useful for monitoring covalently closed circular DNA activity, and predicting hepatitis B e-antigen seroconversion or viral rebound after nucleos(t)ide analog cessation. Data on serum HBV-RNA quasispecies, however, is scarce. It is therefore important to develop methodologies to thoroughly analyze this quasispecies, ensuring the elimination of any residual HBV-DNA. Studying circulating HBV-RNA quasispecies may facilitate achieving functional cure of HBV infection. To establish a next-generation sequencing (NGS) methodology for analyzing serum HBV-RNA and comparing it with DNA quasispecies. Thirteen untreated chronic hepatitis B patients, showing different HBV-genotypes and degrees of severity of liver disease were enrolled in the study and a serum sample with HBV-DNA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients, a Promising Marker of Infection Follow-Up

  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Tabernero, David|||0000-0002-1146-4084
  • Rodriguez-Algarra, Francisco|||0000-0002-4134-2141
  • Palom, Adriana|||0000-0002-0130-1302
  • Sopena, Sara|||0000-0002-3309-5486
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Roade, Luisa|||0000-0002-8160-9613
  • Kuchta, Alison
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Quer, Josep|||0000-0003-0014-084X
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Vila, Marta|||0000-0001-9303-5189
  • Casillas, Rosario|||0000-0002-6758-6734
  • García-García, Selene|||0000-0001-7697-2058
  • Esteban, Rafael|||0000-0001-5280-392X
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log higher than corresponding RNA levels and were stable over 5 years of observation. While only five of 52 treated patients had DNA levels below the lower limit of quantification (10 IU/mL) at the end of follow-up, 13 had HBV RNA levels persistently above this limit, including eight with undetectable DNA. In samples with undetectable core-related antigen we observed a median HBsAg titer 2.7-fold higher than in samples with undetectable RNA (adjusted P = 0.012). Detectable HBV RNA with undetectable HBV DNA was a negative predictor of HBsAg decrease to a level ≤100 IU/mL (P = 0.03). In naive patients the difference between HBV DNA and RNA was higher than previously reported. HBV RNA rapidly decreased during treatment. However, in some cases, it was detectable even after years of effective therapy, being a negative predictor of HBsAg decrease. The investigational RNA assay for use on the Cobas 6800/8800 instruments is a sensitive and standardized method that could be applied in general management of HBV infection. IMPORTANCE This study focused on the quantification of circulating HBV RNA by using a standardized and sensitive assay. Thanks to this system we observed a higher difference between circulating HBV DNA and RNA than previously reported. In treated patients, HBV RNA decreased together with DNA, although some patients presented detectable levels even after years of successful antiviral treatment, suggesting a persistent viral transcription. Of note, the detection of viral RNA when HBV DNA is undetectable was a negative predictor of HBsAg decrease to a level ≤100 IU/mL. This assay could be extremely helpful in HBV patients management to study viral transcription and to identify those treated patients that may achieve sustained viral suppression.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Hepatitis B Virus Variants with Multiple Insertions and/or Deletions in the X Open Reading Frame 3′ End: Common Members of Viral Quasispecies in Chronic Hepatitis B Patients

  • Garcia Garcia, Selene
  • Caballero Garralda, Andrea
  • Tabernero, David
  • Rodriguez-Algarra, Francisco
  • Quer Sivila, Josep
  • Riveiro Barciela, Maria del Mar
  • Homs, Maria
  • Pacín Ruiz, Beatriz
  • Vila Salvador, Marta
  • Ferrer Costa, Roser
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Hepatitis B virus; Insertions; Next-generation sequencing, Virus de l'hepatitis B; Insercions; Seqüenciació de nova generació, Virus de la hepatitis B; Inserciones; Secuenciación de próxima generación, Deletions in the 3′ end region of the hepatitis B virus (HBV) X open reading frame (HBX) may affect the core promoter (Cp) and have been frequently associated with hepatocellular carcinoma (HCC). The aim of this study was to investigate the presence of variants with deletions and/or insertions (Indels) in this region in the quasispecies of 50 chronic hepatitis B (CHB) patients without HCC. We identified 103 different Indels in 47 (94%) patients, in a median of 3.4% of their reads (IQR, 1.3–8.4%), and 25% (IQR, 13.1–40.7%) of unique sequences identified in each quasispecies (haplotypes). Of those Indels, 101 (98.1%) caused 44 different altered stop codons, the most commonly observed were at positions 128, 129, 135, and 362 (putative position). Moreover, 39 (37.9%) Indels altered the TATA-like box (TA) sequences of Cp; the most commonly observed caused TA2 + TA3 fusion, creating a new putative canonical TATA box. Four (8%) patients developed negative clinical outcomes after a median follow-up of 9.4 (8.7–12) years. In conclusion, we observed variants with Indels in the HBX 3′ end in the vast majority of our CHB patients, some of them encoding alternative versions of HBx with potential functional roles, and/or alterations in the regulation of transcription., This research was funded by Instituto de Salud Carlos III and co-financed by the European Regional Development Fund (ERDF), grant number PI18/01436; PI19/00301; and by the Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297. The APC was funded by the grant PI18/01436.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up

  • Riveiro Barciela, Maria del Mar
  • Tabernero, David
  • Rodriguez-Algarra, Francisco
  • Palom Agusti, Adriana
  • Sopena Santisteve, Sara
  • Kuchta, Alison
  • Ferrer Costa, Roser
  • Quer Sivila, Josep
  • Pacín Ruíz, Beatriz
  • Vila Salvador, Marta
  • Casillas Gomez, Rosario
  • Garcia Garcia, Selene
  • Esteban Mur, Rafael
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Roade Tato, Maria luisa
  • Rando Segura, Ariadna
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Antiviral treatment; Biomonitoring, Tratamiento antiviral; Biomonitorización, Tractament antiviral; Biomonitorització, The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV RNA through a standardized and sensitive assay in follow-up samples from both naive and treated patients as a marker of infection evolution. HBV DNA (HBV DNA for use in Cobas 6800/8800 Automated Roche Molecular Systems), RNA (Roche HBV RNA Investigational Assay for use in the Cobas 6800/8800; Roche), HBeAg and HBsAg (Elycsys HBsAg chemiluminescence immunoassay by Cobas 8000; Roche), and core-related antigen (Lumipulse G chemiluminescence assay; Fujirebio) levels were measured in cohorts of untreated or nucleos(t)ide treated, HBV-infected subjects in an outpatient hospital setting. HBV DNA levels in untreated people were 3.6 log10 higher than corresponding RNA levels and were stable over 5 years of observation. While only five of 52 treated patients had DNA levels below the lower limit of quantification (10 IU/mL) at the end of follow-up, 13 had HBV RNA levels persistently above this limit, including eight with undetectable DNA. In samples with undetectable core-related antigen we observed a median HBsAg titer 2.7-fold higher than in samples with undetectable RNA (adjusted P = 0.012). Detectable HBV RNA with undetectable HBV DNA was a negative predictor of HBsAg decrease to a level ≤100 IU/mL (P = 0.03). In naive patients the difference between HBV DNA and RNA was higher than previously reported. HBV RNA rapidly decreased during treatment. However, in some cases, it was detectable even after years of effective therapy, being a negative predictor of HBsAg decrease. The investigational RNA assay for use on the Cobas 6800/8800 instruments is a sensitive and standardized method that could be applied in general management of HBV infection. IMPORTANCE This study focused on the quantification of circulating HBV RNA by using a standardized and sensitive assay. Thanks to this system we observed a higher difference between circulating HBV DNA and RNA than previously reported. In treated patients, HBV RNA decreased together with DNA, although some patients presented detectable levels even after years of successful antiviral treatment, suggesting a persistent viral transcription. Of note, the detection of viral RNA when HBV DNA is undetectable was a negative predictor of HBsAg decrease to a level ≤100 IU/mL. This assay could be extremely helpful in HBV patients management to study viral transcription and to identify those treated patients that may achieve sustained viral suppression., This study was supported by grants from the Institute of Health Carlos III (grant PI17/02233 and PI18/01436) and by the European Regional Development Fund (ERDF). The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.